SNP-array lesions in core binding factor acute myeloid leukemia

Oncotarget
Nicolas DuployezClaude Preudhomme

Abstract

Acute myeloid leukemia (AML) with t(8;21) and inv(16), together referred as core binding factor (CBF)-AML, are recognized as unique entities. Both rearrangements share a common pathophysiology, the disruption of the CBF, and a relatively good prognosis. Experiments have demonstrated that CBF rearrangements were insufficient to induce leukemia, implying the existence of cooperating events. To explore these aberrations, we performed single nucleotide polymorphism (SNP)-array in a well-annotated cohort of 198 patients with CBF-AML. Excluding breakpoint-associated lesions, the most frequent events included loss of a sex chromosome (53%), deletions at 9q21 (12%) and 7q36 (9%) in patients with t(8;21) compared with trisomy 22 (13%), trisomy 8 (10%) and 7q36 deletions (12%) in patients with inv(16). SNP-array revealed novel recurrent genetic alterations likely to be involved in CBF-AML leukemogenesis.ZBTB7Amutations (20% of t(8;21)-AML) were shown to be a target of copy-neutral losses of heterozygosity (CN-LOH) at chromosome 19p.FOXP1focal deletions were identified in 5% of inv(16)-AML while sequence analysis revealed that 2% carriedFOXP1truncating mutations. Finally,CCDC26disruption was found in both subtypes (4.5% of the whole cohor...Continue Reading

References

Feb 8, 2003·Current Opinion in Genetics & Development·James R Downing
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Aug 31, 2006·British Journal of Haematology·Frederick R AppelbaumElihu H Estey
Dec 23, 2008·Cancer Genetics and Cytogenetics·Michael MikulasovichVesna Najfeld
Jul 7, 2009·Nature Genetics·Sanjay SheteRichard S Houlston
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ina RadtkeJames R Downing
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramon V TiuJaroslaw P Maciejewski
Jan 29, 2010·Blood·Christine O'KeefeJaroslaw P Maciejewski
Mar 23, 2010·Blood·Stefan HeinrichsA Thomas Look
Dec 14, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Juha GrönholmMika Rämet
Aug 14, 2012·American Journal of Hematology·Jelena D MilosevicRobert Kralovics
Oct 2, 2012·Cancer Letters·Masuko KatohMasaru Katoh
Oct 29, 2014·Expert Review of Hematology·Nicolas DuployezClaude Preudhomme
Mar 17, 2016·Blood·Nicolas DuployezClaude Preudhomme
Jun 3, 2016·Nature Communications·Luise HartmannPhilipp A Greif
Oct 25, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wei Peng, Airen Jiang
Nov 1, 2016·Nature Genetics·Zachary J FaberJames R Downing

❮ Previous
Next ❯

Citations

Sep 21, 2018·American Society of Clinical Oncology Educational Book·Andrew KuykendallJohn S Welch
Aug 4, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J WalkerClara D Bloomfield
Apr 30, 2020·Cancer Letters·Sanjay GuptaShashank Kumar
Jul 3, 2021·Genes·Julie QuessadaMarina Lafage-Pochitaloff

❮ Previous
Next ❯

Methods Mentioned

BETA
chromosomal aberrations
flow cytometry

Clinical Trials Mentioned

NCT00428558
NCT00149162

Software Mentioned

UCSC Genome Browser
SIFT
Polyphen
Chromosome Analysis Suite ( ChAS )
SPSS Statistics
Kaluza
Genomic Recurrent Event ViEwer ( GREVE )
SeqNext
Affymetrix

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.